Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Dr. Jörg Reinhardt to leave Bayer HealthCare

Leverkusen, Germany, January 23, 2013 – Dr. Jörg Reinhardt (56), Chairman of the Board of Management of Bayer HealthCare AG and a member of the Bayer AG Executive Council, will not renew his contract when it expires in summer 2013. Instead he intends to stand for election as new Director of Swiss healthcare company Novartis AG and designated non-executive Chairman of the Board at its annual general meeting to be held at the end of February with a view to assuming that office on August 1, 2013. Reinhardt will end his active service with Bayer effective February 28, 2013.

Bayer AG Management Board member Prof. Wolfgang Plischke (61), whose responsibilities currently include Technology, Innovation and Sustainability, will take over the function of Chairman at Bayer HealthCare in addition to his existing duties until a successor is appointed. Prior to his appointment to the Bayer AG Board of Management on March 1, 2006, Plischke had worked in the health care field for 25 years, latterly as General Manager of what was then the Pharmaceuticals Business Group.

"With his experience and his commitment, Jörg has played a major part in the very positive development of Bayer HealthCare in recent years," said Bayer CEO Dr. Marijn Dekkers. "However, we accept his decision to continue his career in his adopted country of Switzerland and wish him all the best for the future."

Jörg Reinhardt has been Chairman of the Board of Management of Bayer HealthCare AG since August 15, 2010. Born on March 11, 1956 in Homburg in the German state of Saarland, Reinhardt studied pharmaceutical sciences at Saarland University in Saarbrücken. After obtaining his doctorate in 1981, he started his career with Sandoz, which became part of Novartis in 1996, holding various managerial positions of increasing responsibility, including Global Head of Pharmaceutical Development and CEO of the Vaccines & Diagnostics Division. In 2008 he became Chief Operating Officer (COO) of the Novartis group.

In April 2012, Reinhardt was appointed to the Board of Directors of Lonza Group AG, Basel, Switzerland. Lonza is a global company that provides products and services for the life sciences industry. Reinhardt is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

He is married and has two adult children.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.